KYMR vs. QGEN, VTRS, ASND, MRNA, BBIO, BPMC, VRNA, ROIV, ELAN, and RVMD
Should you be buying Kymera Therapeutics stock or one of its competitors? The main competitors of Kymera Therapeutics include Qiagen (QGEN), Viatris (VTRS), Ascendis Pharma A/S (ASND), Moderna (MRNA), BridgeBio Pharma (BBIO), Blueprint Medicines (BPMC), Verona Pharma PLC American Depositary Share (VRNA), Roivant Sciences (ROIV), Elanco Animal Health (ELAN), and Revolution Medicines (RVMD). These companies are all part of the "pharmaceutical products" industry.
Kymera Therapeutics vs. Its Competitors
Qiagen (NYSE:QGEN) and Kymera Therapeutics (NASDAQ:KYMR) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, dividends, earnings and analyst recommendations.
Qiagen has a net margin of 4.68% compared to Kymera Therapeutics' net margin of -409.07%. Qiagen's return on equity of 14.61% beat Kymera Therapeutics' return on equity.
Qiagen has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Qiagen, indicating that it is currently the more affordable of the two stocks.
In the previous week, Kymera Therapeutics had 7 more articles in the media than Qiagen. MarketBeat recorded 11 mentions for Kymera Therapeutics and 4 mentions for Qiagen. Kymera Therapeutics' average media sentiment score of 0.72 beat Qiagen's score of 0.33 indicating that Kymera Therapeutics is being referred to more favorably in the news media.
70.0% of Qiagen shares are owned by institutional investors. 9.0% of Qiagen shares are owned by insiders. Comparatively, 16.0% of Kymera Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Qiagen has a beta of 0.68, meaning that its share price is 32% less volatile than the S&P 500. Comparatively, Kymera Therapeutics has a beta of 2.18, meaning that its share price is 118% more volatile than the S&P 500.
Qiagen presently has a consensus price target of $49.40, suggesting a potential upside of 4.02%. Kymera Therapeutics has a consensus price target of $59.11, suggesting a potential upside of 34.93%. Given Kymera Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Kymera Therapeutics is more favorable than Qiagen.
Summary
Kymera Therapeutics beats Qiagen on 9 of the 17 factors compared between the two stocks.
Get Kymera Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for KYMR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding KYMR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Kymera Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:KYMR) was last updated on 7/8/2025 by MarketBeat.com Staff
Free KYMR Stock Alerts